MRI Scan and Intra-labyrinthine Schwannoma
- Conditions
- Schwannoma
- Registration Number
- NCT03580850
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Age 18-80 years
- Have intra-labyrinthine schwannoma
- Have benefited from an MRI with gadolinium injection on the MRI 3T with interpretable sequences of good quality
- Subject giving their consent for their participation
- Subjects who benefited, between 2009 and 2016, from an MRI of the external auditory canals, with gadolinous product injection and on the 3 Tesla MRI, in which a diagnosis of intra labyrinthine schwannoma was made
Exclusion Criteria
- Refusal to participate in the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA alone 1 hour after the realization of the MRI
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie schwannoma growth in the inner ear and how might gadolinium contrast agents influence their detection on T1 MRI sequences?
How does the use of gadolinium in T1 MRI sequences compare to FIESTA-C for diagnosing intra-labyrinthine schwannoma in terms of diagnostic accuracy and sensitivity?
Are there specific biomarkers associated with intra-labyrinthine schwannoma that could enhance patient selection for MRI diagnostic protocols using gadolinium contrast?
What are the potential adverse events of intravenous gadolinium administration in schwannoma imaging and how can they be managed in clinical practice?
What alternative contrast agents or imaging modalities are being explored for schwannoma detection, and how do they compare to the methods used in NCT03580850?
Trial Locations
- Locations (1)
Service Imagerie 1
🇫🇷Strasbourg, France
Service Imagerie 1🇫🇷Strasbourg, FranceFrancis VEILLON, MD, PhDPrincipal InvestigatorAïna VENKATASAMY, MDSub InvestigatorAnne KAROL, MDSub Investigator